Skip to main content
Top
Published in: Advances in Therapy 6/2016

Open Access 01-06-2016 | Review

Quality of Life in Glaucoma: A Review of the Literature

Authors: Luciano Quaranta, Ivano Riva, Chiara Gerardi, Francesco Oddone, Irene Floriano, Anastasios G. P. Konstas

Published in: Advances in Therapy | Issue 6/2016

Login to get access

Abstract

The ultimate goal of glaucoma management is the preservation of patients’ visual function and quality of life (QoL). The disease itself as well as the medical or surgical treatment can have an enormous impact on a patient’s QoL. Even the mere diagnosis of a chronic, irreversible, potentially blinding disorder can adversely affect the patient’s sense of well-being and QoL by eliciting significant anxiety. Patients with primary open-angle glaucoma rarely present with visual symptoms, at least early in the course of the disease. A better understanding of patient-reported QoL can improve patient–physician interaction and enhance treatment adherence by customizing treatment options based on individual patient profile, thus optimizing long-term prognosis. These aspects are summarized and critically appraised in this article.
Literature
2.
go back to reference Felce D, Perry J. Quality of life: its definition and measurement. Res Dev Disabil. 1995;16:51–74.PubMedCrossRef Felce D, Perry J. Quality of life: its definition and measurement. Res Dev Disabil. 1995;16:51–74.PubMedCrossRef
3.
go back to reference Courtney-Long E, Carroll D, Zhang Q, et al. Prevalence of disability and disability type among adults—United States. MMWR Morb Mortal Wkly Rep. 2013;2015:777–83. Courtney-Long E, Carroll D, Zhang Q, et al. Prevalence of disability and disability type among adults—United States. MMWR Morb Mortal Wkly Rep. 2013;2015:777–83.
4.
go back to reference Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains Eye Study. J Am Geriatr Soc. 1998;46:58–64.PubMedCrossRef Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains Eye Study. J Am Geriatr Soc. 1998;46:58–64.PubMedCrossRef
5.
go back to reference Ivers RQ, Norton R, Cumming RG, Butler M, Campbell AJ. Visual impairment and risk of hip fracture. Am J Epidemiol. 2000;152:633–9.PubMedCrossRef Ivers RQ, Norton R, Cumming RG, Butler M, Campbell AJ. Visual impairment and risk of hip fracture. Am J Epidemiol. 2000;152:633–9.PubMedCrossRef
6.
go back to reference Ribeiro MV, Hasten-Reiter Junior HN, Ribeiro EA, et al. Association between visual impairment and depression in the elderly: a systematic review. Arq Bras Oftalmol. 2015;78:197–201.PubMedCrossRef Ribeiro MV, Hasten-Reiter Junior HN, Ribeiro EA, et al. Association between visual impairment and depression in the elderly: a systematic review. Arq Bras Oftalmol. 2015;78:197–201.PubMedCrossRef
7.
go back to reference McGwin G Jr, Xie A, Mays A, et al. Visual field defects and the risk of motor vehicle collisions among patients with glaucoma. Invest Ophthalmol Vis Sci. 2005;46:4437–41.PubMedCrossRef McGwin G Jr, Xie A, Mays A, et al. Visual field defects and the risk of motor vehicle collisions among patients with glaucoma. Invest Ophthalmol Vis Sci. 2005;46:4437–41.PubMedCrossRef
8.
go back to reference Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013;1:e339–49.PubMedCrossRef Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013;1:e339–49.PubMedCrossRef
9.
go back to reference American Academy of Ophtalmology. Eye disease statistics. 2015: American Academy of Ophthalmology Guidelines. American Academy of Ophtalmology. Eye disease statistics. 2015: American Academy of Ophthalmology Guidelines.
10.
go back to reference Nirmalan PK, Tielsch JM, Katz J, et al. Relationship between vision impairment and eye disease to vision-specific quality of life and function in rural India: the Aravind Comprehensive Eye Survey. Invest Ophthalmol Vis Sci. 2005;46:2308–12.PubMedCrossRef Nirmalan PK, Tielsch JM, Katz J, et al. Relationship between vision impairment and eye disease to vision-specific quality of life and function in rural India: the Aravind Comprehensive Eye Survey. Invest Ophthalmol Vis Sci. 2005;46:2308–12.PubMedCrossRef
11.
go back to reference Broman AT, Munoz B, Rodriguez J, et al. The impact of visual impairment and eye disease on vision-related quality of life in a Mexican-American population: proyecto VER. Invest Ophthalmol Vis Sci. 2002;43:3393–8.PubMed Broman AT, Munoz B, Rodriguez J, et al. The impact of visual impairment and eye disease on vision-related quality of life in a Mexican-American population: proyecto VER. Invest Ophthalmol Vis Sci. 2002;43:3393–8.PubMed
12.
go back to reference Knudtson MD, Klein BE, Klein R, Cruickshanks KJ, Lee KE. Age-related eye disease, quality of life, and functional activity. Arch Ophthalmol. 2005;123:807–14.PubMedCrossRef Knudtson MD, Klein BE, Klein R, Cruickshanks KJ, Lee KE. Age-related eye disease, quality of life, and functional activity. Arch Ophthalmol. 2005;123:807–14.PubMedCrossRef
13.
go back to reference Nutheti R, Shamanna BR, Nirmalan PK, et al. Impact of impaired vision and eye disease on quality of life in Andhra Pradesh. Invest Ophthalmol Vis Sci. 2006;47:4742–8.PubMedCrossRef Nutheti R, Shamanna BR, Nirmalan PK, et al. Impact of impaired vision and eye disease on quality of life in Andhra Pradesh. Invest Ophthalmol Vis Sci. 2006;47:4742–8.PubMedCrossRef
14.
go back to reference Wu SY, Hennis A, Nemesure B, Leske MC, Barbados Eye Studies Group. Impact of glaucoma, lens opacities, and cataract surgery on visual functioning and related quality of life: the Barbados Eye Studies. Invest Ophthalmol Vis Sci. 2008;49:1333–8.PubMedCrossRef Wu SY, Hennis A, Nemesure B, Leske MC, Barbados Eye Studies Group. Impact of glaucoma, lens opacities, and cataract surgery on visual functioning and related quality of life: the Barbados Eye Studies. Invest Ophthalmol Vis Sci. 2008;49:1333–8.PubMedCrossRef
15.
go back to reference Bullinger M. Ensuring international equivalence of quality of life measures: problems and approaches to solution. In: Orley J, Kuyken W, editors. Quality of life assessment: international perspectives. Heidelberg: Springer; 1994. p. 33–40.CrossRef Bullinger M. Ensuring international equivalence of quality of life measures: problems and approaches to solution. In: Orley J, Kuyken W, editors. Quality of life assessment: international perspectives. Heidelberg: Springer; 1994. p. 33–40.CrossRef
16.
go back to reference Power M, Harper A, Bullinger M. The World Health Organization WHOQOL-100: tests of the universality of quality of Life in 15 different cultural groups worldwide. Health Psychol. 1999;18:495–505.PubMedCrossRef Power M, Harper A, Bullinger M. The World Health Organization WHOQOL-100: tests of the universality of quality of Life in 15 different cultural groups worldwide. Health Psychol. 1999;18:495–505.PubMedCrossRef
17.
go back to reference Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.PubMedCrossRef Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.PubMedCrossRef
18.
go back to reference Kurtin PS, Davies AR, Meyer KB, DeGiacomo JM, Kantz ME. Patient-based health status measures in outpatient dialysis. Early experiences in developing an outcomes assessment program. Med Care. 1992;30:MS136–49.PubMedCrossRef Kurtin PS, Davies AR, Meyer KB, DeGiacomo JM, Kantz ME. Patient-based health status measures in outpatient dialysis. Early experiences in developing an outcomes assessment program. Med Care. 1992;30:MS136–49.PubMedCrossRef
19.
go back to reference Nerenz DR, Repasky DP, Whitehouse FW, Kahkonen DM. Ongoing assessment of health status in patients with diabetes mellitus. Med Care. 1992;30:MS112–24.PubMedCrossRef Nerenz DR, Repasky DP, Whitehouse FW, Kahkonen DM. Ongoing assessment of health status in patients with diabetes mellitus. Med Care. 1992;30:MS112–24.PubMedCrossRef
20.
go back to reference Kantz ME, Harris WJ, Levitsky K, Ware JE Jr, Davies AR. Methods for assessing condition-specific and generic functional status outcomes after total knee replacement. Med Care. 1992;30:MS240–52.PubMedCrossRef Kantz ME, Harris WJ, Levitsky K, Ware JE Jr, Davies AR. Methods for assessing condition-specific and generic functional status outcomes after total knee replacement. Med Care. 1992;30:MS240–52.PubMedCrossRef
21.
go back to reference Wachtel T, Piette J, Mor V, et al. Quality of life in persons with human immunodeficiency virus infection: measurement by the Medical Outcomes Study instrument. Ann Intern Med. 1992;116:129–37.PubMedCrossRef Wachtel T, Piette J, Mor V, et al. Quality of life in persons with human immunodeficiency virus infection: measurement by the Medical Outcomes Study instrument. Ann Intern Med. 1992;116:129–37.PubMedCrossRef
22.
go back to reference Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care. 1991;29:786–98.PubMedCrossRef Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care. 1991;29:786–98.PubMedCrossRef
24.
go back to reference Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337–43.PubMedCrossRef Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337–43.PubMedCrossRef
25.
go back to reference Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ. 2003;4:222–31.PubMedCrossRef Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ. 2003;4:222–31.PubMedCrossRef
26.
go back to reference Gordon MO, Kass MA. The ocular hypertension treatment study: design and baseline description of the participants. Arch Ophthalmol. 1999;117:573–83.PubMedCrossRef Gordon MO, Kass MA. The ocular hypertension treatment study: design and baseline description of the participants. Arch Ophthalmol. 1999;117:573–83.PubMedCrossRef
27.
go back to reference Wilson MR, Coleman AL, Yu F, et al. Functional status and well-being in patients with glaucoma as measured by the Medical Outcomes Study Short Form-36 questionnaire. Ophthalmology. 1998;105:2112–6.PubMedCrossRef Wilson MR, Coleman AL, Yu F, et al. Functional status and well-being in patients with glaucoma as measured by the Medical Outcomes Study Short Form-36 questionnaire. Ophthalmology. 1998;105:2112–6.PubMedCrossRef
28.
go back to reference Odberg T, Jakobsen JE, Hultgren SJ, Halseide R. The impact of glaucoma on the quality of life of patients in Norway. II. Patient response correlated to objective data. Acta Ophthalmol Scand. 2001;79:121–4.PubMedCrossRef Odberg T, Jakobsen JE, Hultgren SJ, Halseide R. The impact of glaucoma on the quality of life of patients in Norway. II. Patient response correlated to objective data. Acta Ophthalmol Scand. 2001;79:121–4.PubMedCrossRef
29.
go back to reference Odberg T, Jakobsen JE, Hultgren SJ, Halseide R. The impact of glaucoma on the quality of life of patients in Norway. I. Results from a self-administered questionnaire. Acta Ophthalmol Scand. 2001;79:116–20.PubMedCrossRef Odberg T, Jakobsen JE, Hultgren SJ, Halseide R. The impact of glaucoma on the quality of life of patients in Norway. I. Results from a self-administered questionnaire. Acta Ophthalmol Scand. 2001;79:116–20.PubMedCrossRef
30.
go back to reference Parrish RK 2nd, Gedde SJ, Scott IU, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol. 1997;115:1447–55.PubMedCrossRef Parrish RK 2nd, Gedde SJ, Scott IU, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol. 1997;115:1447–55.PubMedCrossRef
31.
go back to reference Cypel MC, Kasahara N, Atique D, et al. Quality of life in patients with glaucoma who live in a developing country. Int Ophthalmol. 2004;25:267–72.PubMedCrossRef Cypel MC, Kasahara N, Atique D, et al. Quality of life in patients with glaucoma who live in a developing country. Int Ophthalmol. 2004;25:267–72.PubMedCrossRef
32.
go back to reference Mills T, Law SK, Walt J, Buchholz P, Hansen J. Quality of life in glaucoma and three other chronic diseases: a systematic literature review. Drugs Aging. 2009;26:933–50.PubMedCrossRef Mills T, Law SK, Walt J, Buchholz P, Hansen J. Quality of life in glaucoma and three other chronic diseases: a systematic literature review. Drugs Aging. 2009;26:933–50.PubMedCrossRef
33.
go back to reference Kobelt G, Jonsson B, Bergstrom A, et al. Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden. Acta Ophthalmol Scand. 2006;84:363–71.PubMedCrossRef Kobelt G, Jonsson B, Bergstrom A, et al. Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden. Acta Ophthalmol Scand. 2006;84:363–71.PubMedCrossRef
34.
go back to reference Aspinall PA, Johnson ZK, Azuara-Blanco A, et al. Evaluation of quality of life and priorities of patients with glaucoma. Invest Ophthalmol Vis Sci. 2008;49:1907–15.PubMedCrossRef Aspinall PA, Johnson ZK, Azuara-Blanco A, et al. Evaluation of quality of life and priorities of patients with glaucoma. Invest Ophthalmol Vis Sci. 2008;49:1907–15.PubMedCrossRef
35.
go back to reference Vandenbroeck S, De Geest S, Zeyen T, Stalmans I, Dobbels F. Patient-reported outcomes (PRO’s) in glaucoma: a systematic review. Eye (Lond). 2011;25:555–77.CrossRef Vandenbroeck S, De Geest S, Zeyen T, Stalmans I, Dobbels F. Patient-reported outcomes (PRO’s) in glaucoma: a systematic review. Eye (Lond). 2011;25:555–77.CrossRef
36.
go back to reference Varma R, Richman EA, Ferris FL 3rd, Bressler NM. Use of patient-reported outcomes in medical product development: a report from the 2009 NEI/FDA clinical trial endpoints symposium. Invest Ophthalmol Vis Sci. 2010;51:6095–103.PubMedPubMedCentralCrossRef Varma R, Richman EA, Ferris FL 3rd, Bressler NM. Use of patient-reported outcomes in medical product development: a report from the 2009 NEI/FDA clinical trial endpoints symposium. Invest Ophthalmol Vis Sci. 2010;51:6095–103.PubMedPubMedCentralCrossRef
37.
go back to reference Leidy NK. Functional status and the forward progress of merry-go-rounds: toward a coherent analytical framework. Nurs Res. 1994;43:196–202.PubMedCrossRef Leidy NK. Functional status and the forward progress of merry-go-rounds: toward a coherent analytical framework. Nurs Res. 1994;43:196–202.PubMedCrossRef
38.
go back to reference Turano KA, Geruschat DR, Stahl JW, Massof RW. Perceived visual ability for independent mobility in persons with retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1999;40:865–77.PubMed Turano KA, Geruschat DR, Stahl JW, Massof RW. Perceived visual ability for independent mobility in persons with retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1999;40:865–77.PubMed
39.
go back to reference Turano KA, Massof RW, Quigley HA. A self-assessment instrument designed for measuring independent mobility in RP patients: generalizability to glaucoma patients. Invest Ophthalmol Vis Sci. 2002;43:2874–81.PubMed Turano KA, Massof RW, Quigley HA. A self-assessment instrument designed for measuring independent mobility in RP patients: generalizability to glaucoma patients. Invest Ophthalmol Vis Sci. 2002;43:2874–81.PubMed
40.
go back to reference Walt JG, Rendas-Baum R, Kosinski M, Patel V. Psychometric evaluation of the glaucoma symptom identifier. J Glaucoma. 2011;20:148–59.PubMedCrossRef Walt JG, Rendas-Baum R, Kosinski M, Patel V. Psychometric evaluation of the glaucoma symptom identifier. J Glaucoma. 2011;20:148–59.PubMedCrossRef
41.
go back to reference Mangione CM, Berry S, Spritzer K, et al. Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. Arch Ophthalmol. 1998;116:227–33.PubMed Mangione CM, Berry S, Spritzer K, et al. Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. Arch Ophthalmol. 1998;116:227–33.PubMed
42.
go back to reference Mangione CM, Lee PP, Pitts J, et al. Psychometric properties of the national eye institute visual function questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol. 1998;116:1496–504.PubMedCrossRef Mangione CM, Lee PP, Pitts J, et al. Psychometric properties of the national eye institute visual function questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol. 1998;116:1496–504.PubMedCrossRef
43.
go back to reference Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item national eye institute visual function questionnaire. Arch Ophthalmol. 2001;119:1050–8.PubMedCrossRef Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item national eye institute visual function questionnaire. Arch Ophthalmol. 2001;119:1050–8.PubMedCrossRef
44.
go back to reference Hyman LG, Komaroff E, Heijl A, et al. Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmology. 2005;112:1505–13.PubMedCrossRef Hyman LG, Komaroff E, Heijl A, et al. Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmology. 2005;112:1505–13.PubMedCrossRef
45.
go back to reference Leske MC, Heijl A, Hyman L, Bengtsson B. Early manifest glaucoma trial: design and baseline data. Ophthalmology. 1999;106:2144–53.PubMedCrossRef Leske MC, Heijl A, Hyman L, Bengtsson B. Early manifest glaucoma trial: design and baseline data. Ophthalmology. 1999;106:2144–53.PubMedCrossRef
46.
go back to reference Gedde SJ, Schiffman JC, Feuer WJ, et al. The tube versus trabeculectomy study: design and baseline characteristics of study patients. Am J Ophthalmol. 2005;140:275–87.PubMedCrossRef Gedde SJ, Schiffman JC, Feuer WJ, et al. The tube versus trabeculectomy study: design and baseline characteristics of study patients. Am J Ophthalmol. 2005;140:275–87.PubMedCrossRef
47.
go back to reference Bechetoille A, Arnould B, Bron A, et al. Measurement of health-related quality of life with glaucoma: validation of the Glau-QoL 36-item questionnaire. Acta Ophthalmol. 2008;86:71–80.PubMedCrossRef Bechetoille A, Arnould B, Bron A, et al. Measurement of health-related quality of life with glaucoma: validation of the Glau-QoL 36-item questionnaire. Acta Ophthalmol. 2008;86:71–80.PubMedCrossRef
48.
go back to reference Janz NK, Wren PA, Lichter PR, et al. Quality of life in newly diagnosed glaucoma patients: the collaborative initial glaucoma treatment study. Ophthalmology. 2001;108:887–97 (discussion 898).PubMedCrossRef Janz NK, Wren PA, Lichter PR, et al. Quality of life in newly diagnosed glaucoma patients: the collaborative initial glaucoma treatment study. Ophthalmology. 2001;108:887–97 (discussion 898).PubMedCrossRef
49.
go back to reference Mills RP, Janz NK, Wren PA, Guire KE. Correlation of visual field with quality-of-life measures at diagnosis in the collaborative initial glaucoma treatment study (CIGTS). J Glaucoma. 2001;10:192–8.PubMedCrossRef Mills RP, Janz NK, Wren PA, Guire KE. Correlation of visual field with quality-of-life measures at diagnosis in the collaborative initial glaucoma treatment study (CIGTS). J Glaucoma. 2001;10:192–8.PubMedCrossRef
50.
go back to reference Burr JM, Kilonzo M, Vale L, Ryan M. Developing a preference-based Glaucoma Utility Index using a discrete choice experiment. Optom Vis Sci. 2007;84:797–808.PubMedCrossRef Burr JM, Kilonzo M, Vale L, Ryan M. Developing a preference-based Glaucoma Utility Index using a discrete choice experiment. Optom Vis Sci. 2007;84:797–808.PubMedCrossRef
51.
go back to reference Atkinson MJ, Stewart WC, Fain JM, et al. A new measure of patient satisfaction with ocular hypotensive medications: the treatment satisfaction survey for intraocular pressure (TSS-IOP). Health Qual Life Outcomes. 2003;1:67.PubMedPubMedCentralCrossRef Atkinson MJ, Stewart WC, Fain JM, et al. A new measure of patient satisfaction with ocular hypotensive medications: the treatment satisfaction survey for intraocular pressure (TSS-IOP). Health Qual Life Outcomes. 2003;1:67.PubMedPubMedCentralCrossRef
52.
go back to reference Day DG, Sharpe ED, Atkinson MJ, Stewart JA, Stewart WC. The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients. Eye (Lond). 2006;20:583–90.CrossRef Day DG, Sharpe ED, Atkinson MJ, Stewart JA, Stewart WC. The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients. Eye (Lond). 2006;20:583–90.CrossRef
53.
go back to reference Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA. Validation of a questionnaire for comparing the tolerability of ophthalmic medications. Ophthalmology. 1997;104:334–42.PubMedCrossRef Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA. Validation of a questionnaire for comparing the tolerability of ophthalmic medications. Ophthalmology. 1997;104:334–42.PubMedCrossRef
54.
go back to reference European Glaucoma Society. Terminology and guidelines for glaucoma. IV ed. Savona: Editrice DOGMA; 2014. European Glaucoma Society. Terminology and guidelines for glaucoma. IV ed. Savona: Editrice DOGMA; 2014.
55.
go back to reference National Institute for Health and Care Excellence. Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension [CG85]. London: National Collaborating Centre for Acute Care; 2009. National Institute for Health and Care Excellence. Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension [CG85]. London: National Collaborating Centre for Acute Care; 2009.
56.
go back to reference Thygesen J, Aagren M, Arnavielle S, et al. Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries. Curr Med Res Opin. 2008;24:1763–70.PubMedCrossRef Thygesen J, Aagren M, Arnavielle S, et al. Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries. Curr Med Res Opin. 2008;24:1763–70.PubMedCrossRef
57.
58.
go back to reference Peters D, Heijl A, Brenner L, Bengtsson B. Visual impairment and vision-related quality of life in the Early Manifest Glaucoma Trial after 20 years of follow-up. Acta Ophthalmol. 2015;93:745–52. Peters D, Heijl A, Brenner L, Bengtsson B. Visual impairment and vision-related quality of life in the Early Manifest Glaucoma Trial after 20 years of follow-up. Acta Ophthalmol. 2015;93:745–52.
59.
go back to reference Musch DC, Lichter PR, Guire KE, Standardi CL. The collaborative initial glaucoma treatment study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999;106:653–62.PubMedCrossRef Musch DC, Lichter PR, Guire KE, Standardi CL. The collaborative initial glaucoma treatment study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999;106:653–62.PubMedCrossRef
60.
go back to reference Wolfram C, Lorenz K, Breitscheidel L, Verboven Y, Pfeiffer N. Health- and vision-related quality of life in patients with ocular hypertension or primary open-angle glaucoma. Ophthalmologica. 2013;229:227–34.PubMedCrossRef Wolfram C, Lorenz K, Breitscheidel L, Verboven Y, Pfeiffer N. Health- and vision-related quality of life in patients with ocular hypertension or primary open-angle glaucoma. Ophthalmologica. 2013;229:227–34.PubMedCrossRef
61.
go back to reference Viswanathan AC, McNaught AI, Poinoosawmy D, et al. Severity and stability of glaucoma: patient perception compared with objective measurement. Arch Ophthalmol. 1999;117:450–4.PubMedCrossRef Viswanathan AC, McNaught AI, Poinoosawmy D, et al. Severity and stability of glaucoma: patient perception compared with objective measurement. Arch Ophthalmol. 1999;117:450–4.PubMedCrossRef
62.
go back to reference Iester M, Zingirian M. Quality of life in patients with early, moderate and advanced glaucoma. Eye (Lond). 2002;16:44–9.CrossRef Iester M, Zingirian M. Quality of life in patients with early, moderate and advanced glaucoma. Eye (Lond). 2002;16:44–9.CrossRef
63.
go back to reference Globe DR, Schoua-Glusberg A, Paz S, et al. Using focus groups to develop a culturally sensitive methodology for epidemiological surveys in a Latino population: findings from the Los Angeles Latino Eye Study (LALES). Ethn Dis. 2002;12:259–66.PubMed Globe DR, Schoua-Glusberg A, Paz S, et al. Using focus groups to develop a culturally sensitive methodology for epidemiological surveys in a Latino population: findings from the Los Angeles Latino Eye Study (LALES). Ethn Dis. 2002;12:259–66.PubMed
64.
go back to reference McKean-Cowdin R, Wang Y, Wu J, et al. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology. 2008;115(941–948):e941.CrossRef McKean-Cowdin R, Wang Y, Wu J, et al. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology. 2008;115(941–948):e941.CrossRef
65.
go back to reference Richman J, Lorenzana LL, Lankaranian D, et al. Relationships in glaucoma patients between standard vision tests, quality of life, and ability to perform daily activities. Ophthalmic Epidemiol. 2010;17:144–51.PubMedCrossRef Richman J, Lorenzana LL, Lankaranian D, et al. Relationships in glaucoma patients between standard vision tests, quality of life, and ability to perform daily activities. Ophthalmic Epidemiol. 2010;17:144–51.PubMedCrossRef
66.
go back to reference Friedman DS, Freeman E, Munoz B, Jampel HD, West SK. Glaucoma and mobility performance: the Salisbury eye evaluation project. Ophthalmology. 2007;114:2232–7.PubMedCrossRef Friedman DS, Freeman E, Munoz B, Jampel HD, West SK. Glaucoma and mobility performance: the Salisbury eye evaluation project. Ophthalmology. 2007;114:2232–7.PubMedCrossRef
67.
go back to reference Haymes SA, Leblanc RP, Nicolela MT, Chiasson LA, Chauhan BC. Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci. 2007;48:1149–55.PubMedCrossRef Haymes SA, Leblanc RP, Nicolela MT, Chiasson LA, Chauhan BC. Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci. 2007;48:1149–55.PubMedCrossRef
68.
go back to reference Haymes SA, LeBlanc RP, Nicolela MT, Chiasson LA, Chauhan BC. Glaucoma and on-road driving performance. Invest Ophthalmol Vis Sci. 2008;49:3035–41.PubMedCrossRef Haymes SA, LeBlanc RP, Nicolela MT, Chiasson LA, Chauhan BC. Glaucoma and on-road driving performance. Invest Ophthalmol Vis Sci. 2008;49:3035–41.PubMedCrossRef
70.
go back to reference van Gestel A, Webers CA, Beckers HJ, et al. The relationship between visual field loss in glaucoma and health-related quality-of-life. Eye (Lond). 2010;24:1759–69.CrossRef van Gestel A, Webers CA, Beckers HJ, et al. The relationship between visual field loss in glaucoma and health-related quality-of-life. Eye (Lond). 2010;24:1759–69.CrossRef
71.
go back to reference Sawada H, Yoshino T, Fukuchi T, Abe H. Assessment of the vision-specific quality of life using clustered visual field in glaucoma patients. J Glaucoma. 2014;23:81–7.PubMedCrossRef Sawada H, Yoshino T, Fukuchi T, Abe H. Assessment of the vision-specific quality of life using clustered visual field in glaucoma patients. J Glaucoma. 2014;23:81–7.PubMedCrossRef
72.
go back to reference Cheng HC, Guo CY, Chen MJ, et al. Patient-reported vision-related quality of life differences between superior and inferior hemifield visual field defects in primary open-angle glaucoma. JAMA Ophthalmol. 2015;133:269–75. Cheng HC, Guo CY, Chen MJ, et al. Patient-reported vision-related quality of life differences between superior and inferior hemifield visual field defects in primary open-angle glaucoma. JAMA Ophthalmol. 2015;133:269–75.
73.
go back to reference Asaoka R, Crabb DP, Yamashita T, et al. Patients have two eyes!: binocular versus better eye visual field indices. Invest Ophthalmol Vis Sci. 2011;52:7007–11.PubMedCrossRef Asaoka R, Crabb DP, Yamashita T, et al. Patients have two eyes!: binocular versus better eye visual field indices. Invest Ophthalmol Vis Sci. 2011;52:7007–11.PubMedCrossRef
74.
go back to reference Turano KA, Broman AT, Bandeen-Roche K, et al. Association of visual field loss and mobility performance in older adults: Salisbury eye evaluation study. Optom Vis Sci. 2004;81:298–307.PubMedCrossRef Turano KA, Broman AT, Bandeen-Roche K, et al. Association of visual field loss and mobility performance in older adults: Salisbury eye evaluation study. Optom Vis Sci. 2004;81:298–307.PubMedCrossRef
75.
go back to reference Black AA, Wood JM, Lovie-Kitchin JE. Inferior field loss increases rate of falls in older adults with glaucoma. Optom Vis Sci. 2011;88:1275–82.PubMedCrossRef Black AA, Wood JM, Lovie-Kitchin JE. Inferior field loss increases rate of falls in older adults with glaucoma. Optom Vis Sci. 2011;88:1275–82.PubMedCrossRef
76.
go back to reference Medeiros FA, Gracitelli CP, Boer ER, et al. Longitudinal changes in quality of life and rates of progressive visual field loss in glaucoma patients. Ophthalmology. 2015;122:293–301.PubMedCrossRef Medeiros FA, Gracitelli CP, Boer ER, et al. Longitudinal changes in quality of life and rates of progressive visual field loss in glaucoma patients. Ophthalmology. 2015;122:293–301.PubMedCrossRef
77.
go back to reference Agorastos A, Skevas C, Matthaei M, et al. Depression, anxiety, and disturbed sleep in glaucoma. J Neuropsychiatry Clin Neurosci. 2013;25:205–13.PubMedCrossRef Agorastos A, Skevas C, Matthaei M, et al. Depression, anxiety, and disturbed sleep in glaucoma. J Neuropsychiatry Clin Neurosci. 2013;25:205–13.PubMedCrossRef
78.
go back to reference Hollo G, Kothy P, Geczy A, Vargha P. Personality traits, depression, and objectively measured adherence to once-daily prostaglandin analog medication in glaucoma. J Glaucoma. 2009;18:288–92.PubMedCrossRef Hollo G, Kothy P, Geczy A, Vargha P. Personality traits, depression, and objectively measured adherence to once-daily prostaglandin analog medication in glaucoma. J Glaucoma. 2009;18:288–92.PubMedCrossRef
79.
go back to reference Jampel HD, Frick KD, Janz NK, et al. Depression and mood indicators in newly diagnosed glaucoma patients. Am J Ophthalmol. 2007;144:238–44.PubMedCrossRef Jampel HD, Frick KD, Janz NK, et al. Depression and mood indicators in newly diagnosed glaucoma patients. Am J Ophthalmol. 2007;144:238–44.PubMedCrossRef
80.
go back to reference Mabuchi F, Yoshimura K, Kashiwagi K, et al. High prevalence of anxiety and depression in patients with primary open-angle glaucoma. J Glaucoma. 2008;17:552–7.PubMedCrossRef Mabuchi F, Yoshimura K, Kashiwagi K, et al. High prevalence of anxiety and depression in patients with primary open-angle glaucoma. J Glaucoma. 2008;17:552–7.PubMedCrossRef
81.
go back to reference Mabuchi F, Yoshimura K, Kashiwagi K, et al. Risk factors for anxiety and depression in patients with glaucoma. Br J Ophthalmol. 2012;96:821–5.PubMedCrossRef Mabuchi F, Yoshimura K, Kashiwagi K, et al. Risk factors for anxiety and depression in patients with glaucoma. Br J Ophthalmol. 2012;96:821–5.PubMedCrossRef
82.
go back to reference Popescu ML, Boisjoly H, Schmaltz H, et al. Explaining the relationship between three eye diseases and depressive symptoms in older adults. Invest Ophthalmol Vis Sci. 2012;53:2308–13.PubMedCrossRef Popescu ML, Boisjoly H, Schmaltz H, et al. Explaining the relationship between three eye diseases and depressive symptoms in older adults. Invest Ophthalmol Vis Sci. 2012;53:2308–13.PubMedCrossRef
83.
go back to reference Skalicky S, Goldberg I. Depression and quality of life in patients with glaucoma: a cross-sectional analysis using the Geriatric Depression Scale-15, assessment of function related to vision, and the Glaucoma Quality of Life-15. J Glaucoma. 2008;17:546–51.PubMedCrossRef Skalicky S, Goldberg I. Depression and quality of life in patients with glaucoma: a cross-sectional analysis using the Geriatric Depression Scale-15, assessment of function related to vision, and the Glaucoma Quality of Life-15. J Glaucoma. 2008;17:546–51.PubMedCrossRef
84.
go back to reference Wang SY, Singh K, Lin SC. Prevalence and predictors of depression among participants with glaucoma in a nationally representative population sample. Am J Ophthalmol. 2012;154(436–444):e432. Wang SY, Singh K, Lin SC. Prevalence and predictors of depression among participants with glaucoma in a nationally representative population sample. Am J Ophthalmol. 2012;154(436–444):e432.
85.
go back to reference Wilson MR, Coleman AL, Yu F, et al. Depression in patients with glaucoma as measured by self-report surveys. Ophthalmology. 2002;109:1018–22.PubMedCrossRef Wilson MR, Coleman AL, Yu F, et al. Depression in patients with glaucoma as measured by self-report surveys. Ophthalmology. 2002;109:1018–22.PubMedCrossRef
86.
go back to reference Yochim BP, Mueller AE, Kane KD, Kahook MY. Prevalence of cognitive impairment, depression, and anxiety symptoms among older adults with glaucoma. J Glaucoma. 2012;21:250–4.PubMedCrossRef Yochim BP, Mueller AE, Kane KD, Kahook MY. Prevalence of cognitive impairment, depression, and anxiety symptoms among older adults with glaucoma. J Glaucoma. 2012;21:250–4.PubMedCrossRef
87.
go back to reference Janz NK, Wren PA, Guire KE, et al. Fear of blindness in the collaborative initial glaucoma treatment study: patterns and correlates over time. Ophthalmology. 2007;114:2213–20.PubMedCrossRef Janz NK, Wren PA, Guire KE, et al. Fear of blindness in the collaborative initial glaucoma treatment study: patterns and correlates over time. Ophthalmology. 2007;114:2213–20.PubMedCrossRef
88.
go back to reference Ramulu PY, West SK, Munoz B, Jampel HD, Friedman DS. Driving cessation and driving limitation in glaucoma: the Salisbury Eye Evaluation Project. Ophthalmology. 2009;116:1846–53.PubMedPubMedCentralCrossRef Ramulu PY, West SK, Munoz B, Jampel HD, Friedman DS. Driving cessation and driving limitation in glaucoma: the Salisbury Eye Evaluation Project. Ophthalmology. 2009;116:1846–53.PubMedPubMedCentralCrossRef
89.
go back to reference Campbell MK, Bush TL, Hale WE. Medical conditions associated with driving cessation in community-dwelling, ambulatory elders. J Gerontol. 1993;48:S230–4.PubMedCrossRef Campbell MK, Bush TL, Hale WE. Medical conditions associated with driving cessation in community-dwelling, ambulatory elders. J Gerontol. 1993;48:S230–4.PubMedCrossRef
90.
go back to reference Freeman EE, Munoz B, Rubin G, West SK. Visual field loss increases the risk of falls in older adults: the Salisbury eye evaluation. Invest Ophthalmol Vis Sci. 2007;48:4445–50.PubMedCrossRef Freeman EE, Munoz B, Rubin G, West SK. Visual field loss increases the risk of falls in older adults: the Salisbury eye evaluation. Invest Ophthalmol Vis Sci. 2007;48:4445–50.PubMedCrossRef
91.
go back to reference Murphy SL, Dubin JA, Gill TM. The development of fear of falling among community-living older women: predisposing factors and subsequent fall events. J Gerontol A Biol Sci Med Sci. 2003;58:M943–7.PubMedPubMedCentralCrossRef Murphy SL, Dubin JA, Gill TM. The development of fear of falling among community-living older women: predisposing factors and subsequent fall events. J Gerontol A Biol Sci Med Sci. 2003;58:M943–7.PubMedPubMedCentralCrossRef
92.
go back to reference Thomas SA, Friedmann E, Kao CW, et al. Quality of life and psychological status of patients with implantable cardioverter defibrillators. Am J Crit Care. 2006;15:389–98.PubMed Thomas SA, Friedmann E, Kao CW, et al. Quality of life and psychological status of patients with implantable cardioverter defibrillators. Am J Crit Care. 2006;15:389–98.PubMed
93.
go back to reference Nelson CJ, Weinberger MI, Balk E, et al. The chronology of distress, anxiety, and depression in older prostate cancer patients. Oncologist. 2009;14:891–9.PubMedPubMedCentralCrossRef Nelson CJ, Weinberger MI, Balk E, et al. The chronology of distress, anxiety, and depression in older prostate cancer patients. Oncologist. 2009;14:891–9.PubMedPubMedCentralCrossRef
94.
go back to reference Hugues FC, Le Jeunne C. Systemic and local tolerability of ophthalmic drug formulations. An update. Drug Saf. 1993;8:365–80.PubMedCrossRef Hugues FC, Le Jeunne C. Systemic and local tolerability of ophthalmic drug formulations. An update. Drug Saf. 1993;8:365–80.PubMedCrossRef
95.
go back to reference Guldvog B. Can patient satisfaction improve health among patients with angina pectoris? Int J Qual Health Care. 1999;11:233–40.PubMedCrossRef Guldvog B. Can patient satisfaction improve health among patients with angina pectoris? Int J Qual Health Care. 1999;11:233–40.PubMedCrossRef
97.
go back to reference Marquis MS, Davies AR, Ware JE Jr. Patient satisfaction and change in medical care provider: a longitudinal study. Med Care. 1983;21:821–9.PubMedCrossRef Marquis MS, Davies AR, Ware JE Jr. Patient satisfaction and change in medical care provider: a longitudinal study. Med Care. 1983;21:821–9.PubMedCrossRef
98.
go back to reference Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12:393–8.PubMedCrossRef Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12:393–8.PubMedCrossRef
99.
go back to reference Jampel HD, Schwartz GF, Robin AL, et al. Patient preferences for eye drop characteristics: a willingness-to-pay analysis. Arch Ophthalmol. 2003;121:540–6.PubMedCrossRef Jampel HD, Schwartz GF, Robin AL, et al. Patient preferences for eye drop characteristics: a willingness-to-pay analysis. Arch Ophthalmol. 2003;121:540–6.PubMedCrossRef
100.
go back to reference Balkrishnan R, Bond JB, Byerly WG, Camacho FT, Anderson RT. Medication-related predictors of health-related quality of life in glaucoma patients enrolled in a medicare health maintenance organization. Am J Geriatr Pharmacother. 2003;1:75–81.PubMedCrossRef Balkrishnan R, Bond JB, Byerly WG, Camacho FT, Anderson RT. Medication-related predictors of health-related quality of life in glaucoma patients enrolled in a medicare health maintenance organization. Am J Geriatr Pharmacother. 2003;1:75–81.PubMedCrossRef
101.
go back to reference Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53(Suppl 1):S57–68.PubMedCrossRef Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53(Suppl 1):S57–68.PubMedCrossRef
102.
go back to reference Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431–6.PubMedCrossRef Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431–6.PubMedCrossRef
103.
go back to reference Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.PubMedCrossRef Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.PubMedCrossRef
104.
go back to reference Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863–8.PubMedCrossRef Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863–8.PubMedCrossRef
105.
go back to reference Lee BL, Wilson MR. Health-related quality of life in patients with cataract and glaucoma. J Glaucoma. 2000;9:87–94.PubMedCrossRef Lee BL, Wilson MR. Health-related quality of life in patients with cataract and glaucoma. J Glaucoma. 2000;9:87–94.PubMedCrossRef
106.
go back to reference Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350–5.PubMedCrossRef Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350–5.PubMedCrossRef
107.
go back to reference Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264–8.PubMedCrossRef Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264–8.PubMedCrossRef
108.
go back to reference Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312–34.PubMedCrossRef Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312–34.PubMedCrossRef
109.
go back to reference Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86:716–26.PubMedCrossRef Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86:716–26.PubMedCrossRef
110.
go back to reference Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490–6.PubMedCrossRef Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490–6.PubMedCrossRef
111.
go back to reference Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1–9):e2.PubMed Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1–9):e2.PubMed
112.
go back to reference Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615–21.PubMedCrossRef Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615–21.PubMedCrossRef
113.
go back to reference Rossi GC, Pasinetti GM, Scudeller L, Bianchi PE. Ocular surface disease and glaucoma: how to evaluate impact on quality of life. J Ocul Pharmacol Ther. 2013;29:390–4.PubMedCrossRef Rossi GC, Pasinetti GM, Scudeller L, Bianchi PE. Ocular surface disease and glaucoma: how to evaluate impact on quality of life. J Ocul Pharmacol Ther. 2013;29:390–4.PubMedCrossRef
114.
go back to reference Rossi GC, Pasinetti GM, Scudeller L, et al. Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur J Ophthalmol. 2013;23:296–302.PubMedCrossRef Rossi GC, Pasinetti GM, Scudeller L, et al. Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur J Ophthalmol. 2013;23:296–302.PubMedCrossRef
115.
go back to reference Baudouin C, Renard JP, Nordmann JP, et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol. 2013;23:47–54. Baudouin C, Renard JP, Nordmann JP, et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol. 2013;23:47–54.
116.
go back to reference Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88:329–36.PubMedCrossRef Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88:329–36.PubMedCrossRef
117.
go back to reference Januleviciene I, Derkac I, Grybauskiene L, et al. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin Ophthalmol. 2012;6:103–9.PubMedPubMedCentralCrossRef Januleviciene I, Derkac I, Grybauskiene L, et al. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin Ophthalmol. 2012;6:103–9.PubMedPubMedCentralCrossRef
118.
go back to reference Rouland JF, Traverso CE, Stalmans I, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013;97:196–200.PubMedCrossRef Rouland JF, Traverso CE, Stalmans I, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013;97:196–200.PubMedCrossRef
119.
go back to reference Cucherat M, Stalmans I, Rouland JF. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials. J Glaucoma. 2014;23:e69–75.PubMedCrossRef Cucherat M, Stalmans I, Rouland JF. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials. J Glaucoma. 2014;23:e69–75.PubMedCrossRef
120.
go back to reference Aihara M, Otani S, Kozaki J, et al. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. J Glaucoma. 2012;21:60–4.PubMedCrossRef Aihara M, Otani S, Kozaki J, et al. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. J Glaucoma. 2012;21:60–4.PubMedCrossRef
121.
go back to reference Begley CG, Chalmers RL, Abetz L, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci. 2003;44:4753–61.PubMedCrossRef Begley CG, Chalmers RL, Abetz L, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci. 2003;44:4753–61.PubMedCrossRef
122.
go back to reference Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea. 2004;23:762–70.PubMedCrossRef Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea. 2004;23:762–70.PubMedCrossRef
123.
go back to reference Janz NK, Wren PA, Lichter PR, et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001;108:1954–65.PubMedCrossRef Janz NK, Wren PA, Lichter PR, et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001;108:1954–65.PubMedCrossRef
124.
go back to reference Burr J, Azuara-Blanco A, Avenell A, Tuulonen A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev. 2012;9:CD004399.PubMed Burr J, Azuara-Blanco A, Avenell A, Tuulonen A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev. 2012;9:CD004399.PubMed
125.
go back to reference Guedes RA, Guedes VM, Freitas SM, Chaoubah A. Quality of life of medically versus surgically treated glaucoma patients. J Glaucoma. 2013;22:369–73.PubMedCrossRef Guedes RA, Guedes VM, Freitas SM, Chaoubah A. Quality of life of medically versus surgically treated glaucoma patients. J Glaucoma. 2013;22:369–73.PubMedCrossRef
126.
go back to reference Nelson P, Aspinall P, Papasouliotis O, Worton B, O’Brien C. Quality of life in glaucoma and its relationship with visual function. J Glaucoma. 2003;12:139–50.PubMedCrossRef Nelson P, Aspinall P, Papasouliotis O, Worton B, O’Brien C. Quality of life in glaucoma and its relationship with visual function. J Glaucoma. 2003;12:139–50.PubMedCrossRef
127.
go back to reference Ramulu PY, Maul E, Hochberg C, et al. Real-world assessment of physical activity in glaucoma using an accelerometer. Ophthalmology. 2012;119:1159–66.PubMedPubMedCentralCrossRef Ramulu PY, Maul E, Hochberg C, et al. Real-world assessment of physical activity in glaucoma using an accelerometer. Ophthalmology. 2012;119:1159–66.PubMedPubMedCentralCrossRef
128.
go back to reference Freeman EE, Munoz B, West SK, Jampel HD, Friedman DS. Glaucoma and quality of life: the Salisbury eye evaluation. Ophthalmology. 2008;115:233–8.PubMedCrossRef Freeman EE, Munoz B, West SK, Jampel HD, Friedman DS. Glaucoma and quality of life: the Salisbury eye evaluation. Ophthalmology. 2008;115:233–8.PubMedCrossRef
129.
go back to reference Friedman SM, Munoz B, Rubin GS, et al. Characteristics of discrepancies between self-reported visual function and measured reading speed. Salisbury Eye Evaluation Project Team. Invest Ophthalmol Vis Sci. 1999;40:858–64.PubMed Friedman SM, Munoz B, Rubin GS, et al. Characteristics of discrepancies between self-reported visual function and measured reading speed. Salisbury Eye Evaluation Project Team. Invest Ophthalmol Vis Sci. 1999;40:858–64.PubMed
130.
go back to reference Foley DJ, Heimovitz HK, Guralnik JM, Brock DB. Driving life expectancy of persons aged 70 years and older in the United States. Am J Public Health. 2002;92:1284–9.PubMedPubMedCentralCrossRef Foley DJ, Heimovitz HK, Guralnik JM, Brock DB. Driving life expectancy of persons aged 70 years and older in the United States. Am J Public Health. 2002;92:1284–9.PubMedPubMedCentralCrossRef
131.
133.
go back to reference Gilhotra JS, Mitchell P, Ivers R, Cumming RG. Impaired vision and other factors associated with driving cessation in the elderly: the Blue Mountains Eye Study. Clin Exp Ophthalmol. 2001;29:104–7.CrossRef Gilhotra JS, Mitchell P, Ivers R, Cumming RG. Impaired vision and other factors associated with driving cessation in the elderly: the Blue Mountains Eye Study. Clin Exp Ophthalmol. 2001;29:104–7.CrossRef
134.
go back to reference Freeman EE, Munoz B, Turano KA, West SK. Measures of visual function and their association with driving modification in older adults. Invest Ophthalmol Vis Sci. 2006;47:514–20.PubMedCrossRef Freeman EE, Munoz B, Turano KA, West SK. Measures of visual function and their association with driving modification in older adults. Invest Ophthalmol Vis Sci. 2006;47:514–20.PubMedCrossRef
135.
go back to reference Blane A. Through the looking glass: a review of the literature investigating the impact of glaucoma on crash risk, driving performance, and driver self-regulation in older drivers. J Glaucoma. 2014;25:113–21. Blane A. Through the looking glass: a review of the literature investigating the impact of glaucoma on crash risk, driving performance, and driver self-regulation in older drivers. J Glaucoma. 2014;25:113–21.
136.
go back to reference Lee PP. Outcomes and endpoints in glaucoma. J Glaucoma. 1996;5:295–7.PubMed Lee PP. Outcomes and endpoints in glaucoma. J Glaucoma. 1996;5:295–7.PubMed
Metadata
Title
Quality of Life in Glaucoma: A Review of the Literature
Authors
Luciano Quaranta
Ivano Riva
Chiara Gerardi
Francesco Oddone
Irene Floriano
Anastasios G. P. Konstas
Publication date
01-06-2016
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 6/2016
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-016-0333-6

Other articles of this Issue 6/2016

Advances in Therapy 6/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.